Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D A Sychev

Showing results (61-70 of 83) with videos related to

Pageof 9
Sort By:
Advances in Gerontology = Uspekhi Gerontologii|November 19, 2022
[Polypragmasia and interdrug interactions as risk factors of falling in elderly patients.]E S Ilyina, V A Shalygin, O T Bogova, et al.
Klinicheskaia Meditsina|April 11, 2007
[The influence of CYP2C9 genetic polymorphism on the pharmacokinetics and pharmacodynamics of warfarin in patients with constant atrial fibrillation]D A Sychev, Iu A Mikheeva, E S Kropacheva, et al.
Eksperimental'Naia I Klinicheskaia Farmakologiia|August 8, 2018
EFFECT OF CARBAMAZEPINE ON THE ACTIVITY OF CYP3A4 ISOENZYME IN PATIENTS WITH ALCOHOL ADDICTIONM S Zastrozhin, V V Simirnov, D A Sychev, et al.
Psychopharmacology Bulletin|January 2, 2025
Use of a Personalized Clinical Decision Support System for Dosing in Psychopharmacotherapy in Patients with Alcoholic Hallucinosis Based on Pharmacogenomic MarkersVYu Skryabin, A E Petukhov, S A Pozdniakov, et al.
Pharmacogenomics and Personalized Medicine|March 12, 2020
<i>CYP2C19*17</i> May Increase the Risk of Death Among Patients with an Acute Coronary Syndrome and Non-Valvular Atrial Fibrillation Who Receive Clopidogrel and RivaroxabanD A Sychev, O A Baturina, K B Mirzaev, et al.
Kardiologiia|September 14, 2010
[Anticoagulant action and safety of warfarin dosing based on pharmacogenetic testing: results of the first Russian prospective pilot study]D A Sychev, I M Antonov, I V Ignat'ev, et al.
Psychopharmacology Bulletin|April 26, 2021
Impact of the Omics-Based Biomarkers on the Fluvoxamine's Steady-State Concentration, Efficacy and Safety in Patients with Affective Disorders Comorbid with Alcohol Use DisorderM S Zastrozhin, VYu Skryabin, VYu Smirnov, et al.
Psychopharmacology Bulletin|June 7, 2021
Impact of the Omics-Based Biomarkers on the Mirtazapine's Steady-State Concentration, Efficacy and Safety in Patients with Affective Disorders Comorbid with Alcohol Use DisorderM S Zastrozhin, VYu Skryabin, VYu Smirnov, et al.
Psychopharmacology Bulletin|July 11, 2022
Correlation of <i>1846G</i>><i>A</i> Polymorphism of <i>CYP2D6</i> Gene with Haloperidol Efficacy and Safety in Patients with Alcoholic HallucinosesA A Parkhomenko, M S Zastrozhin, VYu Skryabin, et al.
Psychopharmacology Bulletin|November 7, 2022
Association of <b></b> Polymorphism with the Steady-State Concentration of Haloperidol in Patients with Alcohol-Induced Psychotic DisordersA A Parkhomenko, M S Zastrozhin, S A Pozdnyakov, et al.
Pageof 9

Showing results (61-70 of 83) with videos related to

Sort By:
Pageof 9
Advances in Gerontology = Uspekhi Gerontologii|November 19, 2022
[Polypragmasia and interdrug interactions as risk factors of falling in elderly patients.]E S Ilyina, V A Shalygin, O T Bogova, et al.
Klinicheskaia Meditsina|April 11, 2007
[The influence of CYP2C9 genetic polymorphism on the pharmacokinetics and pharmacodynamics of warfarin in patients with constant atrial fibrillation]D A Sychev, Iu A Mikheeva, E S Kropacheva, et al.
Eksperimental'Naia I Klinicheskaia Farmakologiia|August 8, 2018
EFFECT OF CARBAMAZEPINE ON THE ACTIVITY OF CYP3A4 ISOENZYME IN PATIENTS WITH ALCOHOL ADDICTIONM S Zastrozhin, V V Simirnov, D A Sychev, et al.
Psychopharmacology Bulletin|January 2, 2025
Use of a Personalized Clinical Decision Support System for Dosing in Psychopharmacotherapy in Patients with Alcoholic Hallucinosis Based on Pharmacogenomic MarkersVYu Skryabin, A E Petukhov, S A Pozdniakov, et al.
Pharmacogenomics and Personalized Medicine|March 12, 2020
<i>CYP2C19*17</i> May Increase the Risk of Death Among Patients with an Acute Coronary Syndrome and Non-Valvular Atrial Fibrillation Who Receive Clopidogrel and RivaroxabanD A Sychev, O A Baturina, K B Mirzaev, et al.
Kardiologiia|September 14, 2010
[Anticoagulant action and safety of warfarin dosing based on pharmacogenetic testing: results of the first Russian prospective pilot study]D A Sychev, I M Antonov, I V Ignat'ev, et al.
Psychopharmacology Bulletin|April 26, 2021
Impact of the Omics-Based Biomarkers on the Fluvoxamine's Steady-State Concentration, Efficacy and Safety in Patients with Affective Disorders Comorbid with Alcohol Use DisorderM S Zastrozhin, VYu Skryabin, VYu Smirnov, et al.
Psychopharmacology Bulletin|June 7, 2021
Impact of the Omics-Based Biomarkers on the Mirtazapine's Steady-State Concentration, Efficacy and Safety in Patients with Affective Disorders Comorbid with Alcohol Use DisorderM S Zastrozhin, VYu Skryabin, VYu Smirnov, et al.
Psychopharmacology Bulletin|July 11, 2022
Correlation of <i>1846G</i>><i>A</i> Polymorphism of <i>CYP2D6</i> Gene with Haloperidol Efficacy and Safety in Patients with Alcoholic HallucinosesA A Parkhomenko, M S Zastrozhin, VYu Skryabin, et al.
Psychopharmacology Bulletin|November 7, 2022
Association of <b></b> Polymorphism with the Steady-State Concentration of Haloperidol in Patients with Alcohol-Induced Psychotic DisordersA A Parkhomenko, M S Zastrozhin, S A Pozdnyakov, et al.
Pageof 9